adioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid. 2011 Jun;21(6):647-54. doi: 10.1089/thy.2010.0348. Epub 2011 May 12
58. Wise PH, Burnet RB, Ahmad A, HardingPE: Intentional radioiodine ablation in Graves’ disease. Lancet 2:1231, 1975.
58.2. Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radioiodine treatment of hyperthyroidismâ€”prognostic factors for outcome. J Clin Endocrinol Metab 86:3611-3617, 2001.
58.21 Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E. J Clin Endocrinol Metab. 2010 Jan;95(1):201-8 Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
58.3: Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism.J Clin Endocrinol Metab. 2003 Mar;88(3):978-83.
58.31 Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L.Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab. 2006 Aug;91(8):2946-51.
58.4 Santos RB, Romaldini JH, Ward LS A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (¹³¹I) doses for Graves disease treatment.Clin Nucl Med. 2012 Mar;37(3):241-4.
59. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, Fenzi GF, Pinchera A: A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest 13:513-520, 1990.
59.1. Glinoer D, Verelst J. Use of 131-Iodine for the treatment of hyperthyroidism in adults. Annales d Endocrinologie 57:177-185, 1996.
59.2 Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani J-I, et al. 1999 Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves’ disease. Thyroid 9:775.
59.2. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Gravesâ€™ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 86:3488-3493, 2001.
59.3. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after 131-I ablation for Gravesâ€™ disease. J Clin Endocrinol Metab 86:3016-3021, 2001.
59.4: Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131-I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial.J Clin Endocrinol Metab. 2004 Sep;89(9):4439-44.
60. Greig WR, Gillespie FC, Thomson JA, McGirr EM: Iodine-125 treatment for thyrotoxicosis. Lancet 1:755, 1969.
61. Editorial: Radioiodine treatment of thyrotoxicosis. Lancet 1:23,1972.
62. Bremmer WF, Greig WR, McDougall IR: Results of treating 297 thyrotoxic patients with 125I. Lancet 2:281, 1973.
63. Benua RS, Dobyns BM: Isolated compounds in the serum, disappearance of radioactive iodine from the thyroid, and clinical response in patients treated with radioactive iodine. J Clin Endocrinol Metab 15:118, 1955.
63.1. Stensvold AD, Jorde R, Sundsfjord J. Late and transient increases in free T4 after radioiodine treatment for Gravesâ€™ disease. J Endocrinol Invest 20:580-584, 1997.
64. Stanbury JB, Janssen MA: The iodinated albumin-like component of the plasma of thyrotoxic patients. J Clin Endocrinol Metab 22:978, 1962. 64a. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol 55:233-239, 2001.
65. Goldsmith RE: Radioisotope therapy for Graves’ disease. Mayo Clin Proc 47:953, 1972.
66. Slingerland WD, Hershman JM, Dell E, Burrows B: Thyrotropin and PBI in radioiodine-treated hyperthyroid patients. J Clin Endocrinol Metab